The <scp>C5a</scp> receptor antagonist <scp>PMX205</scp> ameliorates experimentally induced colitis associated with increased <scp>IL</scp>‐4 and <scp>IL</scp>‐10

Abstract

Pharmacological inhibition of C5a activity by PMX205 is efficacious in preventing DSS-induced colitis, providing further evidence that targeting CD88 in IBD patients could be a valuable therapeutic option.